Study details
Enrolling now
Defibrotide for Severe COVID-19
Brigham and Women's Hospital
NCT IDNCT04652115ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
42
Study length
about 4.2 years
Ages
18–100
Locations
1 site in MA
About this study
Researchers are testing if defibrotide, a medication, can be safely used in people with severe COVID-19 pneumonia. The trial will evaluate the safety and feasibility of using this treatment in hospitalized patients who need oxygen or mechanical ventilation.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Defibrotide
PhasePhase 2
DrugDefibrotide
Primary goalThe rate of adverse event of special interest (bleeding and hypotension)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
defibrotide
Endpoints
Primary: The rate of adverse event of special interest (bleeding and hypotension)
Body systems
Infectious